In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression: early kinetics of radiolabelled FIAU

被引:45
作者
Haubner, R
Avril, N
Hantzopoulos, PA
Gansbacher, B
Schwaiger, M
机构
[1] Tech Univ Munich, Dept Nucl Med, D-8000 Munich, Germany
[2] Tech Univ Munich, Inst Expt Oncol, D-8000 Munich, Germany
关键词
gene therapy; imaging; HSV1-tk; radiolabelled FIAU;
D O I
10.1007/s002590050035
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Previous studies have shown that the herpes simplex virus type 1 thymidine kinase gene (HSV1-tk), in combination with appropriate radiolabelled substrates (e.g. [I*]-2'-fluoro-2'-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil; I*-FIAU, where the asterisk indicates that any of the various radioactive iodine isotopes can be used), can be used as a reporter gene for in vivo monitoring of gene transfer and expression. The aim of our study was to examine the early kinetics of I*-FIAU and the possibility of utilising iodine-123-labelled FIAU for imaging of gene expression, CMS-5 fibrosarcoma cells were transduced in vitro with the retroviral vector STK containing the HSV1-tk gene. BALB/c mice were inoculated subcutaneously with HSV1-tk(+) and tk(-) cells into both flanks. FAU (2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyluracil was radioiodinated (I-123, I-125) using the iodogen method, High-performance liquid chromatography purification resulted in high specific activity and radiochemical purity for both tracers ([I-123]FIAU and [I-125]FIAU). Biodistribution studies and gamma camera imaging were performed at 0.5, 1, 2 and 4 h p.i. In addition, the genomic DNA of the tumours was isolated for measurement of the activity accumulation resulting from the [I-125]FIAU incorporation. Biodistribution studies 0.5 h p.i, showed tumour/blood and tumour/muscle ratios of 3.8 and 7.2, respectively, for the HSV1-tk(+) tumours, and 0.6 and 1.2, respectively, for negative control tumours, Fast renal elimination of the tracer from the body resulted in rapidly increasing tumour/blood and tumour/muscle ratios which reached values of 32 and 88 at 4 h p.i., respectively. Tracer clearance from blood was bi-exponential. with an initial half-life of 0.6 h followed by a half-life of 4.6 h, The tracer half-life in herpes simplex viral thymidine kinase-expressing tumours was 35.7 h. The highest activity accumulation (20.3%+/-5.7% ID/g) in HSV1-tk(+) tumours was observed 1 h p.i. At that time, about 46% of the total activity found in HSV1-tk(+) tumours was incorporated into genomic DNA, Planar gamma-camera imaging showed a distinct tracer accumulation as early as 0.5 h p.i., with an increase in contrast over time.-These results suggest that sufficient tumour/background ratios for in vivo imaging of HSV1-tk expression with [I-123]FIAU are reached as early as 1 h p.i.
引用
收藏
页码:283 / 291
页数:9
相关论文
共 30 条
[1]   Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG):: A new potential imaging agent for viral infection and gene therapy using PET [J].
Alauddin, MM ;
Conti, PS .
NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (03) :175-180
[2]  
Alauddin MM, 1999, J NUCL MED, V40, p26P
[3]   Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors [J].
Alauddin, MM ;
Shahinian, A ;
Kundu, RK ;
Gordon, EM ;
Conti, PS .
NUCLEAR MEDICINE AND BIOLOGY, 1999, 26 (04) :371-376
[4]   Synthesis of 9-[(3-[F-18]-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([F-18]-FHPG): A potential imaging agent of viral infection and gene therapy using PET [J].
Alauddin, MM ;
Conti, PS ;
Mazza, SM ;
Hamzeh, FM ;
Lever, JR .
NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06) :787-792
[5]  
Anderson WF, 1998, NATURE, V392, P25
[6]   HUMAN SOMATIC GENE-THERAPY - PROGRESS AND PROBLEMS [J].
BRENNER, MK .
JOURNAL OF INTERNAL MEDICINE, 1995, 237 (03) :229-239
[7]  
CHOU TC, 1981, CANCER RES, V41, P3336
[8]   SYNTHESIS OF 2'-FLUORO-5-[C-11]-METHYL-1-BETA-D-ARABINOFURANOSYLURACIL ([C-11]-FMAU) - A POTENTIAL NUCLEOSIDE ANALOG FOR IN-VIVO STUDY OF CELLULAR PROLIFERATION WITH PET [J].
CONTI, PS ;
ALAUDDIN, MM ;
FISSEKIS, JR ;
SCHMALL, B ;
WATANABE, KA .
NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (06) :783-789
[9]  
de Vries E.F.J., 1999, Journal of Labelled Compounds and Radiopharmaceuticals, V42, pS7
[10]  
Dubrovin M, 1999, J NUCL MED, V40, p26P